Pfizer’s Vaccine Meets Goals in Post-Approval Study
This article is for subscribers only.
Pfizer Inc.’s pneumonia vaccine met the goals of a study that was required by U.S. regulators when the therapy was approved for patients at least 50 years old.
The clinical trial called Capita showed the vaccine worked against a first episode of vaccine-type community-acquired pneumonia in patients 65 and older, Pfizer said today in a statement. The Food and Drug Administration approved Prevnar 13 for adults 50 and older in December 2011 on an accelerated basis with the condition the New York company prove the shot protects against pneumonia in post-clearance studies.